VG-161 is under clinical development by Virogin Biotech and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VG-161’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VG-161 overview
VG-161 is under development for the treatment of intrahepatic cholangiocarcinoma, pancreatic ductal adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, metastatic hepatocellular carcinoma, metastatic gastric or gastroesophageal junction adenocarcinoma, bone sarcoma, soft tissue sarcoma, Ewing sarcoma. The drug candidate is an oncolytic virus.It is an attenuated herpes simplex virus type 1 (HSV-1), developed based on Virogin’s Synerlytic Platform, VG161 has a deletion of the ICP34.5 gene to prevent neurovirulence. It is administered through intratumor route. It acts by targeting interleukin-12, interleukin-15, interleukin-15 receptor subunit alpha and programmed cell death 1 ligand 1 (PD-L1). It was also under development for lymphoma, solid tumor, sarcoma and colon cancer.
Virogin Biotech overview
Virogin Biotech is a biopharmaceutical company developing immunotherapies and oncolytic virotherapies for the treatment of cancers and immune diseases. The company’s pipeline products include mRNA vaccines for the treatment of infectious diseases like monkey pox virus, epstein-barr virus, human papilloma virus, and HER2 mRNA vaccine. It’s pipeline products also include oncolytic viral backbone for the treatment of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and other solid tumours. The organisation works in collaboration with research institutes, biotechnology, and pharmaceutical companies. It operates research and development hubs in Vancouver, Canada, and Shanghai, China. Virogin Biotech is headquartered in Vancouver, British Colombia, Canada.
For a complete picture of VG-161’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
